Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving Average – Here’s What Happened

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.39 and traded as high as $3.55. Oramed Pharmaceuticals shares last traded at $3.44, with a volume of 61,539 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research report on Friday, March 27th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Price Performance

The firm has a fifty day simple moving average of $3.39 and a 200-day simple moving average of $2.97. The firm has a market cap of $139.15 million, a P/E ratio of 2.31 and a beta of 1.26.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings results on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. On average, equities analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current year.

Oramed Pharmaceuticals Announces Dividend

The business also recently disclosed a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were paid a $0.25 dividend. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is 16.78%.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ORMP. SB Capital Management Inc purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth approximately $5,415,000. Marshall Wace LLP purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth approximately $738,000. BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 2.7% in the third quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock worth $8,361,000 after purchasing an additional 83,978 shares during the last quarter. HRT Financial LP purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth approximately $131,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth approximately $119,000. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.